Petrelintide
| Clinical data | |
|---|---|
| Other names | ZP8396 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Petrelintide (development name ZP8396)[1] is an amylin analogue dosed once weekly, developed by Zealand Pharma for the treatment of type 2 diabetes and obesity.[2][3][4] Preclinical data suggests it may be more effective in combination with semaglutide.[5]
References
- ^ "ZP8396 (Amylin Analog)". Zealand Pharma A/S. Retrieved 11 March 2024.
- ^ Skarbaliene, Jolanta; Baader-Pagler, Tamara; Eriksson, Per-Olof (2022). "213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats". Diabetes. 71 (Supplement_1). doi:10.2337/db22-213-OR.
- ^ Olsen, Minna B.; HöVelmann, Ulrike; Griffin, Jon; Knudsen, Kim M.; Johansen, Thue; Kendall, David; Heise, Tim (20 June 2023). "92-LB: Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long-Acting Amylin Analog—A Single Ascending Dose Trial". Diabetes. 72 (Supplement_1). doi:10.2337/db23-92-LB.
- ^ "Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions". BioSpace. Retrieved 1 November 2023.
- ^ Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, MA; Henriksen, K. (1 December 2022). "Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models". Biomedicine & Pharmacotherapy. 156: 113842. doi:10.1016/j.biopha.2022.113842. ISSN 0753-3322.